BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32608329)

  • 1. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.
    Chatterjee S; Maity A; Chowdhury S; Islam MA; Muttinini RK; Sen D
    J Biomol Struct Dyn; 2021 Sep; 39(14):5290-5303. PubMed ID: 32608329
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
    Elseginy SA
    J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease.
    Joshi T; Joshi T; Pundir H; Sharma P; Mathpal S; Chandra S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6728-6746. PubMed ID: 32752947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
    J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
    J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.
    Sharma P; Joshi T; Mathpal S; Joshi T; Pundir H; Chandra S; Tamta S
    J Biomol Struct Dyn; 2022 Apr; 40(6):2757-2768. PubMed ID: 33143552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing for coronavirus (COVID-19):
    Elmezayen AD; Al-Obaidi A; Şahin AT; Yelekçi K
    J Biomol Struct Dyn; 2021 May; 39(8):2980-2992. PubMed ID: 32306862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
    Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
    J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
    Kundu D; Selvaraj C; Singh SK; Dubey VK
    J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening of approved clinic drugs with main protease (3CL
    Wang Q; Zhao Y; Chen X; Hong A
    J Biomol Struct Dyn; 2022 Feb; 40(2):685-695. PubMed ID: 32909528
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ibrahim MAA; Abdelrahman AHM; Hegazy MF
    J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.